A subnormal level of BLOOD PLATELETS.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.
A condition in newborns caused by immunity of the mother to PLATELET ALLOANTIGENS on the fetal platelets. The PLATELETS, coated with maternal ANTIBODIES, are destroyed and removed by the fetal MONONUCLEAR PHAGOCYTE SYSTEM. Affected infants may have INTRACRANIAL HEMORRHAGES.
The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.
Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.
Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy.
Any form of purpura in which the PLATELET COUNT is decreased. Many forms are thought to be caused by immunological mechanisms.
Very large BONE MARROW CELLS which release mature BLOOD PLATELETS.
A humoral factor that stimulates the production of thrombocytes (BLOOD PLATELETS). Thrombopoietin stimulates the proliferation of bone marrow MEGAKARYOCYTES and their release of blood platelets. The process is called THROMBOPOIESIS.
A CXC chemokine that is found in the alpha granules of PLATELETS. The protein has a molecular size of 7800 kDa and can occur as a monomer, a dimer or a tetramer depending upon its concentration in solution. Platelet factor 4 has a high affinity for HEPARIN and is often found complexed with GLYCOPROTEINS such as PROTEIN C.
Cell surface receptors that are specific for THROMBOPOIETIN. They signal through interaction with JANUS KINASES such as JANUS KINASE 2.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
Surgical procedure involving either partial or entire removal of the spleen.
A genus of the family BUNYAVIRIDAE comprising many viruses, most of which are transmitted by Phlebotomus flies and cause PHLEBOTOMUS FEVER. The type species is RIFT VALLEY FEVER VIRUS.
The process of generating thrombocytes (BLOOD PLATELETS) from the pluripotent HEMATOPOIETIC STEM CELLS in the BONE MARROW via the MEGAKARYOCYTES. The humoral factor with thrombopoiesis-stimulating activity is designated THROMBOPOIETIN.
A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.
The co-occurrence of pregnancy and a blood disease (HEMATOLOGIC DISEASES) which involves BLOOD CELLS or COAGULATION FACTORS. The hematologic disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS.
Bleeding or escape of blood from a vessel.
A decrease in the number of NEUTROPHILS found in the blood.
Virus diseases caused by the BUNYAVIRIDAE.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE.
A rare, X-linked immunodeficiency syndrome characterized by ECZEMA; LYMPHOPENIA; and, recurrent pyogenic infection. It is seen exclusively in young boys. Typically, IMMUNOGLOBULIN M levels are low and IMMUNOGLOBULIN A and IMMUNOGLOBULIN E levels are elevated. Lymphoreticular malignancies are common.
Agents that prevent clotting.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Disorders caused by abnormalities in platelet count or function.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (BLOOD COAGULATION DISORDERS) or another abnormality causing a structural flaw in the blood vessels (HEMOSTATIC DISORDERS).
Enlargement of the spleen.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Disorders of the blood and blood forming tissues.
A syndrome that is associated with microvascular diseases of the KIDNEY, such as RENAL CORTICAL NECROSIS. It is characterized by hemolytic anemia (ANEMIA, HEMOLYTIC); THROMBOCYTOPENIA; and ACUTE RENAL FAILURE.
Increased numbers of platelets in the peripheral blood. (Dorland, 27th ed)
Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.
Formation and development of a thrombus or blood clot in the blood vessel.
An organoplatinum compound that possesses antineoplastic activity.
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
Condition characterized by splenomegaly, some reduction in the number of circulating blood cells in the presence of a normal or hyperactive bone marrow, and the potential for reversal by splenectomy.
A lymphohematopoietic cytokine that plays a role in regulating the proliferation of ERYTHROID PRECURSOR CELLS. It induces maturation of MEGAKARYOCYTES which results in increased production of BLOOD PLATELETS. Interleukin-11 was also initially described as an inhibitor of ADIPOGENESIS of cultured preadipocytes.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Platelet membrane glycoprotein complex important for platelet adhesion and aggregation. It is an integrin complex containing INTEGRIN ALPHAIIB and INTEGRIN BETA3 which recognizes the arginine-glycine-aspartic acid (RGD) sequence present on several adhesive proteins. As such, it is a receptor for FIBRINOGEN; VON WILLEBRAND FACTOR; FIBRONECTIN; VITRONECTIN; and THROMBOSPONDINS. A deficiency of GPIIb-IIIa results in GLANZMANN THROMBASTHENIA.
An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
A series of progressive, overlapping events, triggered by exposure of the PLATELETS to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.
Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.
The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.
The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).
Purplish or brownish red discoloration, easily visible through the epidermis, caused by hemorrhage into the tissues. When the size of the discolorization is >2-3 cm it is generally called Ecchymoses (ECCHYMOSIS).
The relationship between the dose of an administered drug and the response of the organism to the drug.
A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
An integrin beta subunit of approximately 85-kDa in size which has been found in INTEGRIN ALPHAIIB-containing and INTEGRIN ALPHAV-containing heterodimers. Integrin beta3 occurs as three alternatively spliced isoforms, designated beta3A-C.
A clinically recognized malformation condition caused by a distal 11q deletion. The features of the syndrome are growth retardation, psychomotor retardation, trigonocephaly, divergent intermittent strabismus, epicanthus, telecanthus, broad nasal bridge, short nose with anteverted nostrils, carp-shaped upper lip, retrognathia, low-set dysmorphic ears, bilateral camptodactyly, and hammertoes. Most patients have a THROMBOCYTOPENIA and platelet dysfunction known also as Paris-Trousseau type thrombocytopenia.
WASP protein is mutated in WISKOTT-ALDRICH SYNDROME and is expressed primarily in hematopoietic cells. It is the founding member of the WASP protein family and interacts with CDC42 PROTEIN to help regulate ACTIN polymerization.
Platelet membrane glycoprotein complex essential for normal platelet adhesion and clot formation at sites of vascular injury. It is composed of three polypeptides, GPIb alpha, GPIb beta, and GPIX. Glycoprotein Ib functions as a receptor for von Willebrand factor and for thrombin. Congenital deficiency of the GPIb-IX complex results in Bernard-Soulier syndrome. The platelet glycoprotein GPV associates with GPIb-IX and is also absent in Bernard-Soulier syndrome.
Immunizing agent containing IMMUNOGLOBULIN G anti-Rho(D) used for preventing Rh immunization in Rh-negative individuals exposed to Rh-positive red blood cells.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
A characteristic symptom complex.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
Laboratory tests for evaluating the individual's clotting mechanism.
Antibodies produced by a single clone of cells.
Single-chain polypeptides of about 65 amino acids (7 kDa) from LEECHES that have a neutral hydrophobic N terminus, an acidic hydrophilic C terminus, and a compact, hydrophobic core region. Recombinant hirudins lack tyr-63 sulfation and are referred to as 'desulfato-hirudins'. They form a stable non-covalent complex with ALPHA-THROMBIN, thereby abolishing its ability to cleave FIBRINOGEN.
A familial coagulation disorder characterized by a prolonged bleeding time, unusually large platelets, and impaired prothrombin consumption.
Influenza-like febrile viral disease caused by several members of the BUNYAVIRIDAE family and transmitted mostly by the bloodsucking sandfly Phlebotomus papatasii.
An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.
Organic compounds which contain platinum as an integral part of the molecule.
A genus of the family BUNYAVIRIDAE containing over 150 viruses, most of which are transmitted by mosquitoes or flies. They are arranged in groups defined by serological criteria, each now named for the original reference species (previously called serogroups). Many species have multiple serotypes or strains.
Diseases that result in THROMBOSIS in MICROVASCULATURE. The two most prominent diseases are PURPURA, THROMBOTIC THROMBOCYTOPENIC; and HEMOLYTIC-UREMIC SYNDROME. Multiple etiological factors include VASCULAR ENDOTHELIAL CELL damage due to SHIGA TOXIN; FACTOR H deficiency; and aberrant VON WILLEBRAND FACTOR formation.
Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions.
A subspecialty of internal medicine concerned with morphology, physiology, and pathology of the blood and blood-forming tissues.
Use of HIRUDINS as an anticoagulant in the treatment of cardiological and hematological disorders.
A subtype of HLA-DRB beta chains that includes over 50 allelic variants. The HLA-DRB3 beta-chain subtype is associated with HLA-DR52 serological subtype.
A virulent form of dengue characterized by THROMBOCYTOPENIA and an increase in vascular permeability (grades I and II) and distinguished by a positive pain test (e.g., TOURNIQUET PAIN TEST). When accompanied by SHOCK (grades III and IV), it is called dengue shock syndrome.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Surface glycoproteins on platelets which have a key role in hemostasis and thrombosis such as platelet adhesion and aggregation. Many of these are receptors.
A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).
Antibodies obtained from a single clone of cells grown in mice or rats.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Proteins prepared by recombinant DNA technology.
Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Elements of limited time intervals, contributing to particular results or situations.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
An infant during the first month after birth.
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
Disease having a short and relatively severe course.
Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.
Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
Platelet membrane glycoprotein IIb is an integrin alpha subunit that heterodimerizes with INTEGRIN BETA3 to form PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX. It is synthesized as a single polypeptide chain which is then postranslationally cleaved and processed into two disulfide-linked subunits of approximately 18 and 110 kDa in size.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
Removal of bone marrow and evaluation of its histologic picture.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
Tumors or cancer of the LUNG.
Drugs that act on blood and blood-forming organs and those that affect the hemostatic system.
An abnormal elevation of body temperature, usually as a result of a pathologic process.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
A syndrome of HEMOLYSIS, elevated liver ENZYMES, and low blood platelets count (THROMBOCYTOPENIA). HELLP syndrome is observed in pregnant women with PRE-ECLAMPSIA or ECLAMPSIA who also exhibit LIVER damage and abnormalities in BLOOD COAGULATION.
An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The return of a sign, symptom, or disease after a remission.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
Antiphospholipid antibodies found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase IMMUNOASSAY employing the purified phospholipid antigen CARDIOLIPIN.

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. (1/2544)

Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme of 5-fluorouracil (5-FU) catabolism. We report lymphocytic DPD data concerning a group of 53 patients (23 men, 30 women, mean age 58, range 36-73), treated by 5-FU-based chemotherapy in different French institutions and who developed unanticipated 5-FU-related toxicity. Lymphocyte samples (standard collection procedure) were sent to us for DPD determination (biochemical method). Among the whole group of 53 patients, 19 had a significant DPD deficiency (DD; below 150 fmol min(-1) mg(-1) protein, i.e. less than 70% of the mean value observed from previous population study). There was a greater majority of women in the DD group (15 out of 19, 79%) compared with the remaining 34 patients (15 out of 34, 44%, P<0.014). Toxicity was often severe, leading to patient death in two cases (both women). The toxicity score (sum of WHO grading, theoretical range 0-20) was twice as high in patients with marked DD (below 100 pmol min(-1) mg(-1) protein, n = 11, mean score = 13.2) compared with patients with moderate DD (between 150 and 100 pmol min(-1) mg(-1) protein, n = 8, mean score = 6.8), P = 0.008. In the DD group, there was a high frequency of neurotoxic syndromes (7 out of 19, 37%). The two deceased patients both had severe neurotoxicity. The occurrence of cardiac toxicity was relatively rare (1 out of 19, 5%). These data suggest that women are particularly prone to DPD deficiency and allow a more precise definition of the DD toxicity profile.  (+info)

A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. (2/2544)

2-Amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride (nolatrexed dihydrochloride, Thymitaq, AG337), a specific inhibitor of thymidylate synthase, was developed using protein structure-based drug design. Intravenously administered nolatrexed is active clinically. As oral bioavailability is high (70-100%), nolatrexed was administered orally, 6 hourly for 10 days, at 3-week intervals, and dose escalated from 80 to 572 mg m(-2) day(-1) in 23 patients. Common toxicity criteria (CTC) grade 3 toxicities included nausea, vomiting, stomatitis and liver function test (LFT) abnormalities. Thrombocytopenia (grade 1 or 2) occurred at doses > or = 318 mg m(-2) day(-1) and neutropenia (grade 2) at 429 and 572 mg m(-2) day(-1). An erythematous maculopapular rash occurred at dosages > or = 318 mg m(-2) day(-1) (7 out of 19 patients). LFT abnormalities occurred in two out of six patients (grade 3 or 4 bilirubin and grade 3 alanine transaminase) at 572 mg m(-2) day(-1). Nolatrexed plasma concentrations 1 h after dosing were 6-16 microg ml(-1), and trough 3-8 microg ml(-1), at 572 mg m(-2) day(-1). Inhibition of thymidylate synthase was demonstrated by elevation of plasma deoxyuridine. Six-hourly oral nolatrexed for 10 days was associated with antiproliferative effects, but nausea and vomiting was dose limiting at 572 mg m(-2) day(-1). Nine patients were treated at 429 mg m(-2) day(-1); three out of nine experienced grade 3 nausea, but 17 out of 22 treatment courses were completed (with the co-administration of prophylactic antiemetics) and this dose level could be considered for phase II testing.  (+info)

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. (3/2544)

PURPOSE: To evaluate the feasibility of administering topotecan in combination with paclitaxel and cisplatin without and with granulocyte colony-stimulating factor (G-CSF) support as first-line chemotherapy in women with incompletely resected stage III and stage IV ovarian carcinoma. PATIENTS AND METHODS: Starting doses were paclitaxel 110 mg/m2 administered over 24 hours (day 1), followed by cisplatin 50 mg/m2 over 3 hours (day 2) and topotecan 0.3 mg/m2/d over 30 minutes for 5 consecutive days (days 2 to 6). Treatment was repeated every 3 weeks. After encountering dose-limiting toxicities (DLTs) without G-CSF support, the maximum-tolerated dose was defined as 5 microg/kg of G-CSF subcutaneously starting on day 6. RESULTS: Twenty-one patients received a total of 116 courses at four different dose levels. The DLT was neutropenia. At the first dose level, all six patients experienced grade 4 myelosuppression. G-CSF support permitted further dose escalation of cisplatin and topotecan. Nonhematologic toxicities, primarily fatigue, nausea/vomiting, and neurosensory neuropathy, were observed but were generally mild. Of 15 patients assessable for response, nine had a complete response, four achieved a partial response, and two had stable disease. CONCLUSION: Neutropenia was the DLT of this combination of paclitaxel, cisplatin, and topotecan. The recommended phase II dose is paclitaxel 110 mg/m2 (day 1), followed by cisplatin 75 mg/m2 (day 2) and topotecan 0.3 mg/m2/d (days 2 to 6) with G-CSF support repeated every 3 weeks.  (+info)

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. (4/2544)

PURPOSE: Rituximab was recently approved for use in relapsed, low-grade non-Hodgkin's lymphoma; however, few data exist regarding the safety of this agent in patients with a high number of tumor cells in the blood. METHODS AND RESULTS: After the observation at our institution of a rapid reduction of peripheral-blood tumor cells with associated severe pulmonary infusion-related toxicity in two patients with refractory hematologic malignancies, data on three additional cases were collected from physician-submitted reports of adverse events related to rituximab treatment. Five patients with hematologic malignancies possessing a high number of blood tumor cells were treated with rituximab and developed rapid tumor clearance. The median age was 68 years (range, 26 to 78 years). Patients were diagnosed with B-cell prolymphocytic leukemia (n = 2), chronic lymphocytic leukemia (n = 2), or transformed non-Hodgkin's lymphoma (n = 1). All of these patients had bulky adenopathy or organomegaly. All five patients developed a unique syndrome of severe infusion-related reactions, thrombocytopenia, rapid decrement in circulating tumor cell load, and mild electrolyte evidence of tumor lysis, and all required hospitalization. In addition, one patient developed ascites. These events resolved, and four patients were subsequently treated with rituximab without significant complications. CONCLUSION: Rituximab administration in patients who have a high number of tumor cells in the blood may have an increased likelihood of severe initial infusion-related reactions. These data also suggest that rituximab may have activity in a variety of other lymphoid neoplasms, such as chronic lymphocytic leukemia and B-cell prolymphocytic leukemia.  (+info)

Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. (5/2544)

PURPOSE: Platinum-based chemotherapy currently represents standard treatment for advanced non-small-cell lung cancer. Gemcitabine is one of the most interesting agents currently in use in advanced non-small-cell lung cancer, and high response rates have been reported when it is administered in combination with cisplatin. The aim of the present study was to evaluate the combination of gemcitabine and carboplatin in a phase I-II study. PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB-IV non-small-cell lung cancer received carboplatin at area under the concentration-time curve (AUC) 5 mg/mL/min and gemcitabine at an initial dose of 800 mg/m2, subsequently escalated by 100 mg/m2 per step. Gemcitabine was administered on days 1 and 8 and carboplatin on day 8 of the 28-day cycle. Dose escalation proceeded up to dose-limiting toxicity (DLT), which was defined as grade 4 neutropenia or thrombocytopenia or grade 3 nonhematologic toxicity. RESULTS: Neutropenia was DLT, inasmuch as it occurred in three of five patients receiving gemcitabine 1,200 mg/m2. Nonhematologic toxicities were mild. Gemcitabine 1,100 mg/m2 plus carboplatin AUC 5 was recommended for phase II studies. An objective response was observed in 13 (50%) of 26 patients, including four complete responses (15%) and nine partial responses (35%). Median duration of response was 13 months (range, 3 to 23 months). Median overall survival was 16 months (range, 3 to 26 months). CONCLUSION: The combination of gemcitabine and carboplatin is well tolerated and active. Neutropenia was DLT. The observed activity matches that observable in cisplatin-gemcitabine studies, whereas duration of response and survival are even higher. A phase II trial is under way.  (+info)

A phase I/II study of continuous intra-arterial chemotherapy using an implantable reservoir for the treatment of liver metastases from breast cancer: a Japan Clinical Oncology Group (JCOG) study 9113. JCOG Breast Cancer Study Group. (6/2544)

BACKGROUND: Liver metastasis from breast cancer has a poor prognosis. While there are some reports of good response rates of hepatic metastasis from breast cancer by hepatic intra-arterial infusion chemotherapy, no phase I study including pharmacokinetic analysis has been reported. We performed a phase I/II study of intra-arterial infusion chemotherapy using adriamycin and 5-fluorouracil to find the maximum tolerated dose and response rate in patients with advanced or recurrent breast cancer. METHODS: A hepatic arterial catheter with an access port was inserted into the proper hepatic artery. Patients received 30 mg/m2 adriamycin on days 1 and 8 and 100 mg/m2 5-fluorouracil at level 1, 200 mg/m2 at level 2,300 mg/m2 at level 3 and 400 mg/m2 at level 4 continuously from day 1 through day 14 every 28 days. At least two cycles were required before evaluation. Twenty-eight patients were entered into this study and 26 patients were evaluable. Seventeen patients had hepatic metastasis only, although nine patients had additional metastasis to other sites. RESULTS: Dose-limiting toxicity of thrombocytopenia and neurotoxicity occurred at level 4. Leukocytopenia (ECOG grade 3-4) was observed in five (19%), thrombocytopenia in three (12%) and anemia in two (8%) patients. There were 11 catheter-related complications which were not dose dependent. Seven out of 13 evaluable patients (54%) responded at level 3. The median duration of response was 5.8 months (range, 1-23+) and median survival was 25.3 months (range, 6.2-54.7+). CONCLUSION: Hepatic arterial infusion therapy appears to be safe and effective but catheter-related complications must be overcome before starting a phase III trial.  (+info)

Distinct human immunodeficiency virus strains in the bone marrow are associated with the development of thrombocytopenia. (7/2544)

We analyzed bone marrow and blood from human immunodeficiency virus type 1 (HIV-1)-infected individuals and described the HIV-1 quasispecies in these cellular compartments. HIV-1 isolates from the bone marrow of thrombocytopenic patients contained distinct amino acids in the V3 loop and infected T-cell lines, implicating this virus in the development of thrombocytopenia.  (+info)

Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. (8/2544)

Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare disorder expressed in infancy and characterized by isolated thrombocytopenia and megakaryocytopenia with no physical anomalies. Our previous hematological analysis indicated similarities between human CAMT and murine c-mpl (thrombopoietin receptor) deficiency. Because the c-mpl gene was considered as one of the candidate genes for this disorder, we analyzed the genomic sequence of the c-mpl gene of a 10-year-old Japanese girl with CAMT. We detected two heterozygous point mutations: a C-to-T transition at the cDNA nucleotide position 556 (Q186X) in exon 4 and a single nucleotide deletion of thymine at position 1,499 (1,499 delT) in exon 10. Both mutations were predicted to result in a prematurely terminated c-Mpl protein, which, if translated, lacks all intracellular domains essential for signal transduction. Each of the mutations was segregated from the patient's parents. Accordingly, the patient was a compound heterozygote for two mutations of the c-mpl gene, each derived from one of the parents. The present study suggests that at least a certain type of CAMT is caused by the c-mpl mutation, which disrupts the function of thrombopoietin receptor.  (+info)

We deserve no credit for the muddied waters of heparin-induced thrombocytopenia terminology. The concept of early, mild, nonimmune, clinically inconsequential heparin-induced thrombocytopenia was advanced years ago as heparin-induced thrombocytopenia type 1 (1). In fact, low platelet counts in some hospitalized patients may often be unrelated to heparin and may be due instead to infection, surgery, other drugs, and stresses. The recommendation to designate this as heparin-associated thrombocytopenia to distinguish it from serious heparin-induced thrombocytopenia (2) has not gained wide favor. Furthermore, separating heparin-induced thrombocytopenia from heparin-induced thrombocytopenia with thrombosis syndrome is artificial and misleading, since isolated heparin-induced ...
TY - JOUR. T1 - Delayed-onset heparin-induced thrombocytopenia. AU - Rice, Lawrence. AU - Attisha, Walid K.. AU - Drexler, Alane. AU - Francis, John L.. PY - 2002/2/5. Y1 - 2002/2/5. N2 - Background: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli. Delayed recognition and treatment of heparin-induced thrombocytopenia contribute to poor patient outcomes. Objective: To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin-induced thrombocytopenia are delayed. Design: Retrospective case series. Setting: Three large urban hospitals (with active cardiovascular surgery programs). Patients: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications. Measurements: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody ...
1. Report Introduction. 2. Immune thrombocytopenia (ITP) 2.1. Overview. 2.2. History. 2.3. Immune thrombocytopenia (ITP) Symptoms. 2.4. Causes. 2.5.Pathophysiology. 2.6. Immune thrombocytopenia (ITP) Diagnosis. 2.6.1. Diagnostic Guidelines. 3. Immune thrombocytopenia (ITP) Current Treatment Patterns. 3.1. Immune thrombocytopenia (ITP) Treatment Guidelines. 4. Immune thrombocytopenia (ITP) - DelveInsights Analytical Perspective. 4.1. In-depth Commercial Assessment. 4.1.1. Immune thrombocytopenia (ITP) companies collaborations, Licensing, Acquisition -Deal Value Trends. Assessment Summary. 4.1.2. Immune thrombocytopenia (ITP) Collaboration Deals. Company-Company Collaborations (Licensing / Partnering) Analysis. Company-University Collaborations (Licensing / Partnering) Analysis. Immune thrombocytopenia (ITP) Acquisition Analysis. 5. Therapeutic Assessment. 5.1. Clinical Assessment of Pipeline Drugs. 5.1.1. Assessment by Phase of Development. 5.1.2. Assessment ...
Thrombocytopenia, encountered frequently among patients with HCV-related chronic hepatitis and cirrhosis, is usually aggravated during IFN-based antiviral therapy. In several large-scale clinical trials, the incidence of severe on-treatment thrombocytopenia was 3-5% among all patients with chronic hepatitis C [2-4]. In the current study, severe thrombocytopenia occurred more frequently (12.8%) in patients with baseline thrombocytopenia. Roomer et al. (2010) documented that patients with baseline thrombocytopenia were vulnerable to severe thrombocytopenia [5]. This group also found that severe thrombocytopenia was significantly associated with bleeding events. In the present study, severe thrombocytopenia did occur in some patients during antiviral therapy, but it was not followed by mortality or major morbidity. Instead, severe thrombocytopenia was associated with higher rates of premature discontinuation of therapy.. Thrombocytopenia is one of the extrahepatic manifestations of HCV infection. ...
Thrombocytopenia can be caused by many different underlying disorders. The diagnostic approach to this haematological abnormality may, therefore, be challenging for physicians. Causes of thrombocytopenia may be classified according to decreased production, increased peripheral consumption or destruction, or abnormal distribution of platelets. Additionally, it is important to rule out pseudothrombocytopenia, a laboratory artefact caused in vitro by ethylenediaminetetraacetic acid (EDTA) anticoagulants. Here we discuss the clinical and laboratory evaluation of drug-induced thrombocytopenia based on the description of two patients, one with ceftriaxone-induced thrombocytopenia and the other with heparin-induced thrombocytopenia. Drug-induced thrombocytopenia is rare, but it is an important consideration in the differential diagnosis of thrombocytopenic patients. The aetiology is often not recognised or is ascribed to other complications such as disseminated intravascular coagulation (DIC) or immune ...
Heparin-induced thrombocytopenia is a complication of treatment with the blood-thinner (anticoagulant) heparin that can cause low platelets in the blood and an increased risk of blood clotting (thrombosis). A test for heparin-induced thrombocytopenia (HIT, heparin-PF4) antibody detects these antibodies that develop in some people treated with heparin and helps diagnosis heparin-induced thrombocytopenia (HIT type II).
Heparin-induced thrombocytopenia is a potentially life-threatening complication of heparin or low-molecular-weight heparin administration. We describe the case of a patient with heparin-induced thrombocytopenia complicated by pulmonary embolism, successfully treated with fondaparinux, a factor Xa inhibitor. We also review the literature regarding the use of this anticoagulant in heparin-induced thrombocytopenia complicated by thrombosis. Few treatment options are available in Belgium, and there is little evidence regarding newer anticoagulants. ...
HIT-RADIO is a retrospective chart-review study of patients who had a positive heparin PF-4 antibody test between 1/21/2008 and 9/25/2008 at selected hospitals associated with the Transfusion Medicine/Hemostasis Clinical Trials Network .. Heparin-induced thrombocytopenia (HIT) is a major complication of the administration of heparin and can result in life-threatening thrombosis with or without thrombocytopenia (HIT-T) or can produce thrombocytopenia without clinically symptomatic thrombosis (isolated HIT). Isolated heparin-induced thrombocytopenia is defined as a fall in platelet count associated with a positive heparin PF-4 antibody test, in the absence of clinically overt thrombosis. While the treatment of HIT-T (HIT with thrombosis) with anticoagulation is well established, the risks and treatment of isolated HIT are unclear.. It is anticipated that this data analysis will provide a current overview of the implications of a positive heparin PF-4 antibody test in clinical practice. It should ...
Heparin-induced thrombocytopenia (HIT) is the development of thrombocytopenia (a low platelet count), due to the administration of various forms of heparin, an anticoagulant. HIT predisposes to thrombosis (the abnormal formation of blood clots inside a blood vessel) because platelets release microparticles that activate thrombin, thereby leading to thrombosis. When thrombosis is identified the condition is called heparin-induced thrombocytopenia and thrombosis (HITT). HIT is caused by the formation of abnormal antibodies that activate platelets. If someone receiving heparin develops new or worsening thrombosis, or if the platelet count falls, HIT can be confirmed with specific blood tests. The treatment of HIT requires stopping heparin treatment, and both protection from thrombosis and choice of an agent that will not reduce the platelet count any further. Several alternatives are available for this purpose and mainly used are danaparoid, fondaparinux, argatroban and bivalirudin. While heparin ...
TY - JOUR. T1 - Lepirudin anticoagulation for heparin-induced thrombocytopenia after cardiac surgery in a pediatric patient. AU - Knoderer, Chad A.. AU - Knoderer, Holly M.. AU - Turrentine, Mark. AU - Kumar, Manjusha. PY - 2006/5. Y1 - 2006/5. N2 - A 21-month-old boy received anticoagulation with lepirudin for heparin-induced thrombocytopenia (HIT) after undergoing cardiac surgery and receiving extracorporeal membrane oxygenation (ECMO). This report illustrates the significance of HIT in pediatric patients after cardiac surgery and the successful administration of lepirudin in this setting. To our knowledge, this is the first published report of lepirudin administered to treat HIT in a child after cardiac surgery and ECMO. Although guidelines exist that suggest the potential administration of lepirudin as treatment for children with HIT, further studies are needed to determine the safest yet most effective dosage for this population.. AB - A 21-month-old boy received anticoagulation with ...
Tips to help with your thrombocytopenia: Renal Failure Cause Thrombocytopenia. My thrombocytopenia, Online resources for thrombocytopenia.
Tips to help with your thrombocytopenia: Can Pneumonia Cause Thrombocytopenia. My thrombocytopenia, Online resources for thrombocytopenia.
Table of Contents:. Introduction. Executive Summary. Immune thrombocytopenia: Overview. Pipeline Therapeutics. • Comparative Analysis. Therapeutic Assessment. Immune thrombocytopenia - DelveInsights Analytical Perspective. In-depth Commercial Assessment. • Immune thrombocytopenia companies collaborations, Licensing, Acquisition -Deal Value Trends. Immune thrombocytopenia Collaboration Deals. Late Stage Products (Phase III). • Comparative Analysis. Rozanolixizumab (UCB7665): UCB. Drug profiles in the detailed report…... Mid Stage Products (Phase II). • Comparative Analysis. BIVV-020: Bioverativ. Drug profiles in the detailed report…... Early Stage Products (Phase I/II). • Comparative Analysis. M 254: Momenta Pharmaceuticals. Drug profiles in the detailed report…... Preclinical/Discovery Stage Products. • Comparative Analysis. CNP-105: Cour Pharmaceutical Development. Drug profiles in the detailed report…... Inactive Products. • Comparative Analysis. Immune thrombocytopenia ...
Clinical symptoms associated with this condition include lethargy, fever, melena, hematemesis, hematuria, hematochezia, epistaxis and mucosal petechiations or ecchymotic hemorrhages on the mucous membranes. Many of these symptoms are referable to underlying thromboembolism and/or hemorrhagic episodes[25]. Spontaneous hemorrhage does not typically occur unless platelets are less than 50,000 and some dogs, buccal mucosal bleeding times may be normal. Hematological analysis usually reveals reduced thrombocyte numbers and elevated partial thromboplastin time (normal = 9.6-13.8) and prothrombin time (normal = 7.5-9.9)[26]. Macrothrombocytes and fusiform cytoplasmic inclusion bodies in neutrophils may be observed in some cases (May-Hegglin anomaly). The diagnosis of immune-mediated thrombocytopenia is made by the exclusion of the secondary causes of thrombocytopenia. Bone marrow cytological analysis should be performed to assess appropriate cellularity within the bone marrow to exclude evidence of ...
TY - JOUR. T1 - The Pathophysiology of Immune-mediated Heparin-induced Thrombocytopenia. AU - Reilly, Robert F.. PY - 2003/1/1. Y1 - 2003/1/1. N2 - Heparin-induced thrombocytopenia (HIT) is an important side effect of heparin therapy associated with significant morbidity and mortality if unrecognized. The platelet count typically falls below 150,000/μl 15-14 days after heparin is started. Thrombosis is the major clinical complication. The diagnosis is confirmed with a variety of functional and antigenic assays. Heparin binds to PF4, resulting in a conformational change in the molecule that exposes neo-epitopes that act as immunogens. Antibodies form against the heparin-PF4 complex, the major target antigen. The IgG-heparin-PF4 immune complex binds either via its Fab domain to the platelet surface or via its Fc domain to the FcγIIA receptor on the surface of the platelet, resulting in further platelet activation. Continued release of PF4 from activated platelets leads to increasing PF4-heparin ...
Thrombocytopenia is a disorder in which there are too few platelets and the blood does not clot properly. People who have thrombocytopenia may bleed a lot from an injury because they have an abnormally low number of platelets.. Some conditions or diseases lead to thrombocytopenia because they destroy a persons platelets or interfere with their production. Certain medicines may also cause thrombocytopenia. A person who has a low platelet count with no known cause is said to have immune thrombocytopenic purpura (ITP).. Symptoms of thrombocytopenia include:. ...
Background. The 2008 WHO classification identified refractory cytopenia with unilineage dysplasia (RCUD) as a composite entity encompassing refractory anemia, refractory thrombocytopenia (RT), and refractory neutropenia (RN), characterized by 10% or more dysplastic cells in the bone marrow respective lineage. The diagnosis of RT and RN is complicated by several factors. Diagnosing RT first requires exclusion of familial thrombocytopenia, chronic auto-immune thrombocytopenia, concomitant medications, viral infections, or hypersplenism. Diagnosis of RN should also be made after ruling out differential diagnoses such as ethnic or familial neutropenia, as well as acquired, drug-induced, infection-related or malignancy-related neutropenia. An accurate quantification of dysplasia should be performed in order to distinguish RT or RN from the provisional entity named idiopathic cytopenia of unknown significance (ICUS). Cytogenetic analysis, and possibly in the future somatic mutation analysis (of genes ...
BACKGROUND: Heparin-induced thrombocytopenia (HIT) complicated by severe thrombocytopenia and thrombosis can pose significant treatment challenges. Use of alternative anticoagulants in this setting may increase bleeding risks, especially in patients who have a protracted disease course. Additional therapies are lacking in this severely affected patient population.. METHODS: We describe three patients with HIT who had severe thromboembolism and prolonged thrombocytopenia refractory to standard treatment but who achieved an immediate and sustained response to IVIg therapy. The mechanism of action of IVIg was evaluated in these patients and in five additional patients with severe HIT. The impact of a common polymorphism (H/R 131) in the platelet IgG receptor FcγRIIa on IVIg-mediated inhibition of platelet activation was also examined.. RESULTS: At levels attained in vivo, IVIg inhibits HIT antibody-mediated platelet activation. The constant domain of IgG (Fc) but not the antigen-binding portion ...
Drug-induced thrombocytopenia requires a high suspicion for diagnosis and a broad investigation to exclude other etiologies of low platelets. Cessation of the offending agent often results in recovery of platelet counts. Many medications are known to cause a degree of thrombocytopenia. We present a rare case of severe thrombocytopenia associated with administration of azithromycin.
Pippucci T, Savoia A, Perrotta S, Pujol-Moix N, Noris P, Castegnaro G, Pecci A, Gnan C, Punzo F, Marconi C, Gherardi S, Loffredo G, De Rocco D, Scianguetta S, Barozzi S, Magini P, Bozzi V, Dezzani L, Di Stazio M, Ferraro M, Perini G, Seri M, Balduini CL (2011) Mutations in the 5 UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet 88(1):115-120. https://​doi.​org/​10.​1016/​j.​ajhg.​2010.​12.​006 CrossRefPubMedPubMedCentral ...
Download Chemotherapy-induced thrombocytopenia Market Sample Pages for Chemotherapy-induced thrombocytopenia Market Forecast, emerging companies and epidemiology and market forecast upto 2030.
TY - JOUR. T1 - Platelet measurements versus discharge diagnoses for identification of patients with potential drug-induced thrombocytopenia. T2 - a cross-sectional study in the Netherlands. AU - ten Berg, Maarten J. AU - van Solinge, Wouter W. AU - van den Bemt, Patricia M L A. AU - Huisman, Albert. AU - Schobben, Alfred F A M. AU - Egberts, Toine C G. PY - 2009. Y1 - 2009. N2 - BACKGROUND: In pharmacoepidemiological studies on the risk of drug-induced blood dyscrasias, including drug-induced thrombocytopenia (DIT), hospital discharge diagnoses have been used to identify potential cases. One of the possible limitations of discharge diagnoses is that due to incomplete registration not all potential cases are identified, which may limit statistical power. Clinical laboratory data have been suggested as a data type that is potentially more sensitive for identifying potential cases of adverse drug reactions than discharge diagnoses.OBJECTIVE: To compare the number of patients with potential DIT ...
Heparin-induced thrombocytopenia (HIT) is a drug induced immune mediated thrombocytopenia that affects up to 3% of patients treated with unfractionated heparin (UFH). It is less frequent when low molecular weight heparins (LMWH) are used. Fondaparinux does not seem to induce HIT. A functional and an antigen assay should be performed to confirm the clinical diagnosis of HIT. Immediate cessation of heparin and start of compatible anticoagulant is mandatory when HIT is suspected clinically. Danaparoid (a heparinoid)and the direct thrombin inhibitors lepirudin and argatroban are available for this purpose. Short-term reexposure with heparin, for example during cardiopulmonary bypass, is possible in patients with history of HIT, provided HIT antiodies are no longer detectable. In children systematic data on treatment of HIT are lacking.. ...
A variety of drugs can cause thrombocytopenia. We report on one patient who developed severe refractory thrombocytopenia following abciximab use ...
Background: Thrombocytopenia is not a disease but a symptom. For investigating causes of thrombocytopenia in patients, the aetiology can be achieved by taking a good clinical history, physical examination and basic laboratory tests. Thrombocytopenia has an inverse relation to mortality and morbidity is various febrile illnesses, serial monitoring of platelet counts has prognostic value. This highlights the importance of thrombocytopenia in various febrile disorders. Objective: To assess etiological factors of thrombocytopenia in acute febrile illness in indoor patients in our hospital. To assess the prognosis of acute febrile illness in relation with severity of thrombocytopenia. To correlate platelet count with bleeding and effectiveness of platelet replacement therapy. To assess the complications and mortality in relation to thrombocytopenia. Materials and Methods: The study is a observational randomised case study carried out from January 2016 to September 2017 at C.U. Shah Medical College ...
TY - JOUR. T1 - Trombocitopenia neonatal e hipertensión inducida por el embarazo. AU - Bhat, Y. Ramesh. PY - 2013/12/1. Y1 - 2013/12/1. N2 - Thrombocytopenia in neonates occurs due to various causes, and pregnancy induced hypertension has been implicated as one of the maternal etiologies. The frequency and severity of thrombocytopenia vary. Severity of thrombocytopenia may influence the morbidity, warrant intervention and rarely may lead to life threatening hemorrhages. A better understanding of thrombocytopenia due to this etiology helps optimize the care. In the present review the author discusses the frequency, mechanisms, severity, characteristics and natural course, and management options for neonatal thrombocytopenia due to hypertensive disorders of pregnancy.. AB - Thrombocytopenia in neonates occurs due to various causes, and pregnancy induced hypertension has been implicated as one of the maternal etiologies. The frequency and severity of thrombocytopenia vary. Severity of ...
Platelets are the first responders to a bleeding incident. If the full platelet force does not arrive on the scene, bleeding will continue and peticheae, bruises, and perhaps even hemorrhaging will occur. A decreased platelet force (thrombocytopenia) may be caused by several diseases or disorders. On the other hand, a low platelet count may not actually mean that the full platelet force is not available to respond. It is up to the laboratory professional to determine if there is anything in the collection procedure that has artificially produced this low count. This course will increase your understanding of various authentic causes of thrombocytopenia and will alert you to various causes of spurious thrombocytopenia that you, as a medical laboratory scientist should be able to recognize and correct to prevent false reporting of thrombocytopenia.. See all available courses ». ...
Description of disease Thrombocytopenia. Treatment Thrombocytopenia. Symptoms and causes Thrombocytopenia Prophylaxis Thrombocytopenia
The diagnosis of drug-induced thrombocytopenia is often empirical. A temporal relationship must be present between the initiation of the drug and the development of thrombocytopenia, with no other exp... more
Patients with heparin-induced thrombocytopenia (HIT) are at high risk of thrombosis and should be treated with alternative anticoagulant therapy to reduce complications. The current treatment of choic
Do You Have Immune Thrombocytopenia? Join friendly people sharing true stories in the I Have Immune Thrombocytopenia group. Find support forums, advice and chat with groups who share this life experience. A Immune Thrombocytopenia anonymous support g...
Sepsis is a major risk factor for the development of thrombocytopenia, but few studies have specifically evaluated prognostic importance of thrombocytopenia in patients with sepsis. We investigated the incidence, risk factors, and prognostic importance of thrombocytopenia in adult patients admitted to the intensive care unit (ICU) with sepsis. A retrospective analysis of patients admitted with severe sepsis/septic shock from December 2007 to January 2009 to a 24-bed medical ICU was done. A total of 304 patients were included in the study. The patients mean (±SD) age was 68.8 (±15.8) years. The majority (93.7%) had septic shock, and pneumonia was the most common infection (38.8%). Thrombocytopenia developed in 145 patients (47.6%): 77 (25.3%) at ICU admission and 68 (22.3%) during their hospital course. The median (IQR) duration of thrombocytopenia was 4.4 (1.9-6.9) days. Patients who developed thrombocytopenia had more episodes of major bleeding (14.4% vs. 3.7%, P | 0.01) and received more
Sepsis is a major risk factor for the development of thrombocytopenia, but few studies have specifically evaluated prognostic importance of thrombocytopenia in patients with sepsis. We investigated the incidence, risk factors, and prognostic importance of thrombocytopenia in adult patients admitted to the intensive care unit (ICU) with sepsis. A retrospective analysis of patients admitted with severe sepsis/septic shock from December 2007 to January 2009 to a 24-bed medical ICU was done. A total of 304 patients were included in the study. The patients mean (±SD) age was 68.8 (±15.8) years. The majority (93.7%) had septic shock, and pneumonia was the most common infection (38.8%). Thrombocytopenia developed in 145 patients (47.6%): 77 (25.3%) at ICU admission and 68 (22.3%) during their hospital course. The median (IQR) duration of thrombocytopenia was 4.4 (1.9-6.9) days. Patients who developed thrombocytopenia had more episodes of major bleeding (14.4% vs. 3.7%, P | 0.01) and received more
PF4-Dependent P-Selectin Assay Highly Accurate in Diagnosing Heparin-Induced Thrombocytopenia - Bleeding Disorders, From the Blood Journals, News, Written in Blood - ASH Clinical News
TY - JOUR. T1 - Heparin-induced thrombocytopenia in the critically ill. T2 - Interpreting the 4Ts test in a randomized trial. AU - Crowther, Mark. AU - Cook, Deborah. AU - Guyatt, Gordon. AU - Zytaruk, Nicole. AU - McDonald, Ellen. AU - Williamson, David. AU - Albert, Martin. AU - Dodek, Peter. AU - Finfer, Simon. AU - Vallance, Shirley. AU - Heels-Ansdell, Diane. AU - McIntyre, Lauralyn. AU - Mehta, Sangeeta. AU - Lamontagne, Francois. AU - Muscedere, John. AU - Jacka, Michael. AU - Lesur, Olivier. AU - Kutsiogiannis, Jim. AU - Friedrich, Jan. AU - Klinger, James R.. AU - Qushmaq, Ismael. AU - Burry, Lisa. AU - Khwaja, Kosar. AU - Sheppard, Jo Ann. AU - Warkentin, Theodore E.. AU - Tkaczyk, Andrea. AU - Clarke, France. AU - Hall, Rickand. AU - Rocker, Graeme. AU - Julien, Lisa. AU - Wright, Debbie. AU - Roy, Caroline. AU - Theriault, Judy. AU - Pleasance, Susan. AU - Meade, Maureen. AU - Hand, Lori. AU - Freitag, Andreas. AU - Wynne, Christine. AU - Duffett, Mark. AU - Kho, Michelle. AU - ...
1. What if the pregnant patient with a diagnosis of ideopathic thrombocytopenic purpura does not respond to initial therapy? If a patient with presumptive diagnosis of ITP and platelet count less than 70,000/ul fails to have any response to IV IgG or steroids, diagnosis of congenital thrombocytopenic disorder should be considered. Platelet and WBC morphology should be carefully examined, and genetic analysis for MPL, WAS, and RUNX1 mutations may be performed. Past history of thrombocytopenia or a family history of thrombocytopenia is helpful, as is history of bleeding.. Patients with congenital thrombocytopenia can have more pronounced thrombocytopenia during pregnancy. Patients with ITP can fail to respond to first line therapy, and more aggressive therapy with IV IgG (1gram/kg per day for two days) or high dose IV methylprednisolone (1 gram per day for two days), or combination of both, can be used. Duration of response can be short, in which case splenectomy can be considered prior to 26 ...
Peginterferon alfa-2 with ribavirin is the current standard of care for the treatment of HCV infection; however, severe hematologic effects, including anemia, leukopenia, and thrombocytopenia, may make this treatment less than ideal for patients with HCV. Medications to prevent or treat serious neutropenia and anemia have been established and are commonly used. However, thrombocytopenia remains a barrier to the effective treatment of HCV infection in some patients. Developing a more effective treatment for thrombocytopenia for these patients would decrease the risk of serious bleeding events. It may also improve HCV treatment outcomes by preventing dose modifications or discontinuations of peginterferon alfa-2 and ribavirin due to thrombocytopenia.. Anti-D is an antibody to the Rh (D) antigen on red blood cells. When anti-D attaches to the Rh (D) antigen, immune-mediated destruction of platelets is prevented, helping to alleviate low platelet levels in people with thrombocytopenia. This study ...
Supplemental_Table_1 - Supplemental material for Effects of Shen Cao Granules on Chemotherapy-Induced Thrombocytopenia in Gastrointestinal Cancer Patients: A Randomized Controlled Trial
Amgen - Chemotherapy-induced Thrombocytopenia Therapeutics Market Adopts Innovation to Keep Aggressive Forecast 2026 | Amgen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd. - KSU -
TY - CHAP. T1 - Drug-Induced Thrombocytopenia. AU - Mitchell, W. Beau. AU - Bennett, Carolyn M.. PY - 2013/6/11. Y1 - 2013/6/11. UR - http://www.scopus.com/inward/record.url?scp=84903503927&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84903503927&partnerID=8YFLogxK. U2 - 10.1016/B978-0-12-397164-7.00099-9. DO - 10.1016/B978-0-12-397164-7.00099-9. M3 - Chapter. AN - SCOPUS:84903503927. SN - 9780123971647. SP - 647. EP - 650. BT - Transfusion Medicine and Hemostasis. PB - Elsevier Inc.. ER - ...
TY - JOUR. T1 - Congenital Amegakaryocytic Thrombocytopenia. T2 - A Case Report of Pediatric Twins Undergoing Matched Unrelated Bone Marrow Transplantation. AU - Rao, Amulya A.N.. AU - Gourde, Julia A.. AU - Marri, Preethi. AU - Galardy, Paul J.. AU - Khan, Shakila P.. AU - Rodriguez, Vilmarie. PY - 2015/12/1. Y1 - 2015/12/1. N2 - Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare inherited disorder that presents with thrombocytopenia in infancy and evolves into bone marrow failure over time. Allogeneic hematopoietic stem cell transplant remains the only curative treatment option. We report our experience with identical twin sisters diagnosed with CAMT and treated successfully with matched unrelated donor bone marrow transplants. Before the transplant, 1 twin developed pancytopenia, whereas the other had a relatively benign clinical course. Choice of conditioning regimens was based on their pretransplant bone marrow cellularity and presence or absence of panyhypoplasia. Both twins ...
Background Platelet transfusions are used in modern clinical practice to prevent and treat bleeding in people who are thrombocytopenic due to bone marrow failure. Although considerable advances have been made in platelet transfusion therapy in the last 40 years, some areas continue to provoke debate, especially concerning the use of prophylactic platelet transfusions for the prevention of thrombocytopenic bleeding. This is an update of a Cochrane review first published in 2004, and previously updated in 2012 that addressed four separate questions: prophylactic versus therapeutic-only platelet transfusion policy; prophylactic platelet transfusion threshold; prophylactic platelet transfusion dose; and platelet transfusions compared to alternative treatments. This review has now been split into four smaller reviews looking at these questions individually; this review compares prophylactic platelet transfusion thresholds. Objectives To determine whether different platelet transfusion thresholds for
Severe thrombocytopenia should be corrected by prophylactic platelet transfusion prior to central venous catheter (CVC) insertion, according to national and international guidelines. Even though correction is thought to prevent bleeding complications, evidence supporting the routine administration of prophylactic platelets is absent. Furthermore, platelet transfusion bears inherent risk. Since the introduction of ultrasound-guided CVC placement, bleeding complication rates have decreased. The objective of the current trial is, therefore, to demonstrate that omitting prophylactic platelet transfusion prior to CVC placement in severely thrombocytopenic patients is non-inferior compared to prophylactic platelet transfusion. The PACER trial is an investigator-initiated, national, multicentre, single-blinded, randomised controlled, non-inferior, two-arm trial in haematologic and/or intensive care patients with a platelet count of between 10 and 50 × 109/L and an indication for CVC placement. Consecutive
Chronic immune thrombocytopenia (ITP) is a haematological disorder in which patients predominantly develop skin and mucosal bleeding. Early studies suggested ITP was primarily due to immune-mediated peripheral platelet destruction. However, increasing evidence indicates that an additional component of this disorder is immune-mediated decreased platelet production that cannot keep pace with platelet destruction. Evidence for increased platelet destruction is thrombocytopenia following ITP plasma infusions in normal subjects, in vitro platelet phagocytosis, and decreased platelet survivals in ITP patients that respond to therapies that prevent in vivo platelet phagocytosis; e.g., intravenous immunoglobulin G, anti-D, corticosteroids, and splenectomy. The cause of platelet destruction in most ITP patients appears to be autoantibody-mediated. However, cytotoxic T lymphocyte-mediated platelet (and possibly megakaryocyte) lysis, may also be important. Studies supporting suppressed platelet production ...
TY - JOUR. T1 - Rapid-onset piperacillin-tazobactam induced thrombocytopenia. AU - Shaik, Shamsuddin. AU - Kazi, Haseeb A.. AU - Ender, Peter T.. N1 - Publisher Copyright: © The Author(s) 2015. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.. PY - 2015/4/15. Y1 - 2015/4/15. N2 - Thrombocytopenia can occur from a variety of etiologies. Drug-induced thrombocytopenia is known to occur with beta-lactam medications, but often in the setting of prolonged use. We describe 2 patients who developed rapid-onset thrombocytopenia from piperacillin/tazobactam. Other causes of immediate thrombocytopenia were excluded. These cases describe a rare presentation of rapid-onset thrombocytopenia in a commonly used medication.. AB - Thrombocytopenia can occur from a variety of etiologies. Drug-induced thrombocytopenia is known to occur with beta-lactam medications, but often in the setting of prolonged use. We describe 2 patients who developed rapid-onset thrombocytopenia from piperacillin/tazobactam. ...
Splenectomy in Primary Immune Thrombocytopenia(ITP) Splenectomy represents an effective second-line therapy for the treatment of primary immune thrombocytopenia (ITP). T..
There are no words to describe how sorry I am to hear this news. I just saw your post on FB about how people can help by registering with the bone marrow center. While that helps to possibly find a match, is there a way that people can specifically ask to be a match for her? Is this similar to other type of organ donations where there is a list and people go in an order? Im sorry to ask so many questions at a time when you are just processing everything. Im just trying to figure out ways my family and I may be able to help. Big HUGS to you. ...
What is Thrombocytopenia? Low Platelet Count! Steps to Regain a Healthy Count! What is Thrombocytopenia? It is a Low Platelet Count. There are many factors that can cause thrombocytopenia. The condition can be inherited or acquired. Inherited means your parents pass the gene for the condition to you. Acquired means you arent born with the condition, but you develop it. Sometimes the cause of thrombocytopenia isnt known. In this article I share with you the steps that you can take to regain a healthy coun
Post-transfusion purpura is a rare transfusion-related complication that often goes undiagnosed. It is due to alloimmunization against platelet antigens which leads to acute profound thrombocytopenia following the transfusion of any platelet-containing product (red blood cells or platelets). It is commonly seen in multiparous women. Here, we report a case of post-transfusion purpura in a 56-year-old multiparous woman who developed acute thrombocytopenia seven days following a packed red blood cell transfusion. We will discuss the clinical presentation, diagnosis, workup and treatment of this rare disease. It is important to recognize this entity separately and to include it in the differential diagnosis of acute thrombocytopenia after a recent blood transfusion. Treatment for this condition consists of intravenous immunoglobulins, corticosteroids or plasmapheresis.
Thrombocytopenia in patients with chronic hepatitis C virus (HCV) infection is a major problem. The pathophysiology is multifactorial, with auto-immunogenicity, direct bone marrow suppression, hypersplenism, decreased production of thrombopoietin and therapeutic adverse effect all contributing to thrombocytopenia in different measures. The greatest challenge in the care of chronic HCV patients with thrombocytopenia is the difficulty in initiating or maintaining IFN containing anti-viral therapy. Although at present, it is possible to avoid this challenge with the use of the sole Direct Antiviral Agents ( DAAs) as the primary treatment modality, thrombocytopenia remains of particular interest, especially in cases of advanced liver disease. The increased risk of bleeding with thrombocytopenia may also impede the initiation and maintenance of different invasive diagnostic and therapeutic procedures. While eradication of HCV infection itself is the most practical strategy for the remission of
This is the protocol for a review and there is no abstract. The objectives are as follows: To compare the relative efficacy of different treatments for thrombocytopenia (artificial platelet substitutes, platelet-poor plasma, fibrinogen, rFVIIa, rFXIII, thrombopoietin mimetics, antifibrinolytic drugs or platelet transfusions) in patients with chronic bone marrow failure and to derive a hierarchy of potential alternate treatments to platelet transfusions.
Primary immune thrombocytopenia (ITP) is rare. First-line treatment is corticotherapy. Then, several second-line treatments (SLT) are available: splen...
Abstract:. Heparin-induced thrombocytopenia (HIT) is a rare but potentially severe complication of heparin therapy that is strongly associated with venous and arterial thrombosis (HIT and thrombosis syndrome, HITTS), which requires urgent detection and treatment with a nonheparin anticoagulant. Argatroban, a synthetic direct thrombin inhibitor, is indicated for the treatment and prophylaxis of thrombosis in patients with HIT, including those undergoing percutaneous coronary intervention. Argatroban has a relatively short elimination half-life of approximately 45 minutes, which is predominantly performed via hepatic metabolism. It is derived from L-arginine that selectively and reversibly inhibits thrombin, both clot-bound and free, at the catalytic site. Argatroban anticoagulation has been systematically studied in patients with HIT and HITTS and proved to be a safe and effective agent for this indication. The current review presents the pharmacology of argatroban, data regarding monitoring of ...
Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Academic Article ...
Investigation of a platelet factor 4 polymorphism on the immune response in patients with heparin-induced thrombocytopenia Academic Article ...
PubMedID: 25547706 | [Absence of response to rituximab in patients with refractory primary immune thrombocytopenia]. | Zhonghua yi xue za zhi | 10/1/2014
Thrombocytopenia is an autoimmune disorder in which white blood cell doesnt clot normally . It causes the decrease in platelet level of the blood therefore stop the blood to clot. Usually people think that it is not a big deal to decrease the platelet count but it can lead to dangerous condition when a small cut or gum bleed doesnt stop bleeding . There are many cause of idiopathic thrombocytopenia but the most common cause is due to low level platelet count . This disease occur when the body immune lose the ability of fighting with disease. ...
In patients with low or intermediate-1 (int-1) risk myelodysplastic syndrome (MDS) and thrombocytopenia, use of the thrombopoietin (TPO)-receptor agonist, romiplostim, resulted in a 15-fold increase in platelet response as defined by the International Working Groups (IWG) 2006 criteria for hematologic improvement-platelets (HI-P). The data from this randomized, double-blind, placebo-controlled study was presented at the 53rd American Society of Hematology Annual Meeting and Exposition.
A review in people with blood cancers receiving intensive chemotherapy or a stem cell transplant found that overall giving platelet transfusions when the platelet count is less than 10 x 109/L reduced the number of bleeding events and days with significant bleeding.[15] However, this benefit was only seen in certain patient groups, and people undergoing an autologous stem cell transplant derived no obvious benefit.[15] Despite prophylactic platelet transfusions, people with blood cancers often bleed, and other risk factors for bleeding such as inflammation and duration of thrombocytopenia should be considered.[13]. There is little evidence for the use of preventative platelet transfusions in people with chronic bone marrow failure, such as myelodysplasia or aplastic anemia.[16] Multiple guidelines recommend prophylactic platelet transfusions are not used routinely in people with chronic bone marrow failure, and instead an individualised approach should be taken.[11][10][13]. Several studies have ...
Objective: To analyze the course of maternal diseases and compare pregnancy outcomes in patients with systemic lupus erythematosus (SLE)-associated thrombocytopenia to patients without.Methods: Medical charts of 77 pregnancies in 73 SLE patients were systematically reviewed. Patients were divided into two groups according to the presence or absence of thrombocytopenia. Patients who are new onset SLE during pregnancy were also been studied.Result: Thrombocytopenia was found in 18 (23.3%) of the pregnancies. SLE patients with thrombocytopenia during pregnancy had higher percentage of disease flaring (11/18 versus 14/59, p=0.003) and SLE-Pregnancy Disease Activity Index (7.896.192 versus 2.41 +/- 3.3.89, p=0.001) compared to patients without. Also, patients with thrombocytopenia had a higher percentage of pulmonary, cardiac and multiple organ system involvement. There was a statistically significant difference in preeclampsia and early onset hypertensive disorder induced before 34 weeks as well as ...
To the editor: The platelet count in iron-deficiency anemia is typically elevated. Severe iron deficiency may cause thrombocytopenia (1, 3); this has been shown in children (4). We have been unable to discover any report of low platelets associated with iron-deficiency anemia in an adult. The response to iron in an adult with a severe iron-deficiency anemia and thrombocytopenia but with normal serum folate and vitamin B12 levels is described below; an apparent case of iron-deficiency thrombocytopenia.. A 31-year-old black women presented to the emergency room with flank pain and hematuria of 1 months duration. For the previous year she ...
Diagnosis. Thrombocytopenia is diagnosed based on history, clinical signs, physical examination findings, and laboratory tests. A platelet count is included in a complete blood count (CBC), which will allow your veterinarian to determine the severity of the thrombocytopenia. Other tests may be performed to determine what is causing the low platelet numbers. These may include a blood chemistry panel, urinalysis, radiography (x-rays), ultrasound, tests for immune diseases, tests for infectious disease, and taking a bone marrow sample.. Treatment. Thrombocytopenia needs to be treated as soon as it is recognized. Many of the illnesses that cause thrombocytopenia are not obvious right away. Your veterinarian may choose to start treatment for the most common causes before knowing the exact one. Initial treatments may include blood or plasma transfusions, steroids, and antibiotics. As the diagnosis becomes clear, your veterinarian may customize treatment. Some patients may need to be medicated for ...
TY - JOUR. T1 - Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. AU - Terrault, Norah A.. AU - Hassanein, Tarek. AU - Howell, Charles D.. AU - Joshi, Shobha. AU - Lake, John. AU - Sher, Linda. AU - Vargas, Hugo. AU - McIntosh, Joe. AU - Tang, Shande. AU - Jenkins, Tim M.. PY - 2014/12/1. Y1 - 2014/12/1. N2 - Background & Aims This is a phase II multicentre study to investigate the efficacy and safety of avatrombopag (E5501), an investigational second-generation thrombopoietin receptor agonist, administered one week prior to elective procedures in patients with thrombocytopenia secondary to cirrhosis. Methods Adults with cirrhosis and platelet counts ≥10 to ≤58 × 109/L were randomized to placebo or avatrombopag in two sequential cohorts. Cohort A: placebo vs. one of 3 different doses (100 mg loading dose followed by 20, 40, or 80 mg/day on days 2-7) of a first-generation avatrombopag formulation. Cohort B: placebo vs. one of 2 ...
Gow is a Professor of Medicine and Vice Chief of Research in the Division of Hematology. She received her medical degree from Vanderbilt University, finished her residency in Internal Medicine at Emory University Hospitals, and completed sub-specialty training in Hematology and Oncology at the University of Pennsylvania.. Gows clinical interests are in disorders of hemostasis and thrombosis, with a focus on immune-mediated thrombocytopenias⁠-heparin-induced thrombocytopenia (HIT), immune thrombocytopenia, and thrombotic thrombocytopenic purpura⁠-as well as applications of therapeutic apheresis. Her long-standing research program involves translational studies of heparin-induced thrombocytopenia.. Fundamental contributions from her laboratory include the development of novel animal models for studying the HIT immune response, structural studies of the HIT antigenic complex, discovery of a new class of heparin-dependent antibodies to protamine/heparin complexes in patients undergoing cardiac ...
The Src family kinase (SFK) member SRC is a major target in drug development because it is activated in many human cancers, yet deleterious SRC germline mutations have not been reported. We used genome sequencing and Human Phenotype Ontology patient coding to identify a gain-of-function mutation in SRC causing thrombocytopenia, myelofibrosis, bleeding, and bone pathologies in nine cases. Modeling of the E527K substitution predicts loss of SRCs self-inhibitory capacity, which we confirmed with in vitro studies showing increased SRC kinase activity and enhanced Tyr419 phosphorylation in COS-7 cells overexpressing E527K SRC. The active form of SRC predominates in patients platelets, resulting in enhanced overall tyrosine phosphorylation. Patients with myelofibrosis have hypercellular bone marrow with trilineage dysplasia, and their stem cells grown in vitro form more myeloid and megakaryocyte (MK) colonies than control cells. These MKs generate platelets that are dysmorphic, low in number, highly ...
AbstractRationale:Thrombocytopenia in chronic myelomonocytic leukemia (CMML) is usually attributed to impaired marrow production resulting from cytotoxic drug use or CMML itself (
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by peripheral thrombocyte destruction. In some autoimmune disorders, heat-shock proteins (HSP) are suggested to be an important antigenic factor. In this study, we demonstrated the serum free levels of HSP60, HSP70, anti-HSP60, and anti-HSP70 in ITP patients and healthy controls. Twenty-eight newly diagnosed ITP patients, 35 ITP patients in chronic phase, and 25 healthy controls were enrolled to this study. Serum levels of HSP60, HSP70, anti-HSP60, and anti-HSP70 were determined by the ELISA method. Serum HSP60 levels of newly diagnosed ITP patients were significantly decreased when compared with both chronic phase ITP patients and healthy controls. HSP60 levels of ITP patients (both newly diagnosed and chronic phase) with thrombocyte counts more than 30 x 10(9)/L were significantly increased compared with ITP patients with thrombocyte counts less than 30 x 10(9)/L and there was a positive correlation between thrombocyte counts ...
As to the thrombocytopenic category, there is physiological HIT-I and an immunological (bad) HIT-II. Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy (especially unfractionated heparin [UFH]), with a high risk of potentially catastrophic venous or arterial thrombosis (HITTS) and high mortality. Our group knows of a local death in 2004 that may have been due to HITTS. As with so many other situations in medical diagnosis, arriving at a correct diagnosis requires discerning clinical acumen (which, extremely importantly, serves to increase the prevelance of this disorder in a lab-test population). The HIT antibody disappears to non-detectibility in about 100 days; so, a pre-therapeutic screening testing is not logical.. Heparin fragments with molecular weights larger than 5,000 Kd...in highest concentration in unfractionated heparin (UFH) preparations...are needed to generate HIT IgG antibodies (theoretically, there may be rare IgA or IgM cases). Low molecular ...

No data available that match "thrombocytopenia"

... thrombocytopenia, leucopenia, archival anemia, sicilian ana, esr increase, eosinophilia, arthritis, photosensitivity, chills, ...
  • Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. (medscape.com)
  • This condition, known as fetal and neonatal alloimmune thrombocytopenia, is usually detected after the birth of a symptomatic child who shows signs of bleeding in the skin or in the brain. (nih.gov)
  • Submit your Twitter account related to Neonatal Alloimmune Thrombocytopenia to be featured! (novusbio.com)
  • Submit your blog on Neonatal Alloimmune Thrombocytopenia to be featured! (novusbio.com)
  • The study of Neonatal Alloimmune Thrombocytopenia has been mentioned in research publications which can be found using our bioinformatics tool below. (novusbio.com)
  • These pathways complement our catalog of research reagents for the study of Neonatal Alloimmune Thrombocytopenia including antibodies and ELISA kits against HPSE, ITGA2, RNF130, TNC, ITGB3. (novusbio.com)
  • Explore more on Neonatal Alloimmune Thrombocytopenia below! (novusbio.com)
  • We have 1452 products for the study of Neonatal Alloimmune Thrombocytopenia that can be applied to Flow Cytometry, Western Blot, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits. (novusbio.com)
  • X-linked thrombocytopenia primarily affects the circulatory system, specifically the platelets in the blood. (wikipedia.org)
  • Thrombocytopenia (throm-buh-sye-tuh-PEE-nee-uh) is when there aren't as many normal platelets in the blood as there should be. (kidshealth.org)
  • Thrombocytopenia is a dangerous drop in the number of platelets in the blood. (mskcc.org)
  • It is characterized by low levels of platelets in the blood (thrombocytopenia) and absence (aplasia) of the long, thin bones of the forearms (radii). (rarediseases.org)
  • Thrombocytopenia occurs when there are too few platelets in the blood. (vetstreet.com)
  • Thrombocytopenia (say "throm-buh-sy-tuh-PEE-nee-uh") is a low number of platelets in the blood. (alberta.ca)
  • Thrombocytopenia can be contrasted with the conditions associated with an abnormally high level of platelets in the blood: thrombocythemia (when the cause is unknown), and thrombocytosis (when the cause is known). (wikipedia.org)
  • What is heparin-induced thrombocytopenia? (webmd.com)
  • Heparin-induced thrombocytopenia is a blood disorder marked by a low platelet count caused by an adverse reaction to heparin, a blood thinner given to many hospitalized people to prevent blood clots. (webmd.com)
  • What causes heparin-induced thrombocytopenia (HIT)? (medscape.com)
  • Heparin-induced thrombocytopenia (HIT) is caused by antibodies that bind to complexes of heparin and platelet factor 4 (PF4), activating the platelets and promoting a prothrombotic state. (medscape.com)
  • Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review. (medscape.com)
  • Guideline] Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (medscape.com)
  • An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. (medscape.com)
  • Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. (medscape.com)
  • Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. (medscape.com)
  • B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia. (medscape.com)
  • Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. (medscape.com)
  • Heparin-induced thrombocytopenia: laboratory studies. (medscape.com)
  • Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. (medscape.com)
  • Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. (medscape.com)
  • Heparin-induced thrombocytopenia in medical surgical critical illness. (medscape.com)
  • Heparin-induced thrombocytopenia (HIT) due to heparin flushes: a report of three cases. (medscape.com)
  • Heparin flushes and thrombocytopenia. (medscape.com)
  • Heparin-associated thrombocytopenia in the neurosurgical patient. (medscape.com)
  • Rizzoni WE, Miller K, Rick M, Lotze MT. Heparin-induced thrombocytopenia and thromboembolism in the postoperative period. (medscape.com)
  • Intraoperative heparin flushes and subsequent acute heparin-induced thrombocytopenia. (medscape.com)
  • The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. (medscape.com)
  • Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. (medscape.com)
  • Heparin-induced thrombocytopenia and thrombosis. (medscape.com)
  • Heparin-induced thrombocytopenia (HIT), next to bleeding complications, is the most important side-effect of heparin therapy in cardiac patients and the most frequently found thrombocytopenia induced by medication. (springer.com)
  • Two types of HIT are distinguished on the basis of both severity of disease, and pathophysiology: type I HIT is an early, transient, clinically harmless form of thrombocytopenia, due to direct heparin-induced platelet aggregation. (springer.com)
  • The thrombocytopenia is caused by a pathogenic heparin-dependent IgG antibody (HIT-IgG) that recognizes as its target antigen a complex consisting of heparin and platelet factor IV. (springer.com)
  • Adams JG, Humphrey LJ, Zhang XC (1995) Do patients with heparin-induced thrombocytopenia syndrome have heparin specific antibodies? (springer.com)
  • 1994) Can heparin cause adult respiratory distress syndrome by a similar mechanism as heparin associated thrombocytopenia? (springer.com)
  • Bell WR (1988) Heparin-associated thrombocytopenia and thrombosis. (springer.com)
  • Bell WR, Royall RM (1980) Heparin-associated thrombocytopenia: a comparison of three heparin preparations. (springer.com)
  • Bell WR (1976) Thrombocytopenia occuring during heparin therapy. (springer.com)
  • Bell WR, Tomasulo PA, Alving BA (1976) Thrombocytopenia occuring during the administration of heparin. (springer.com)
  • Blanke H, Lesch M, Strauer BE (1987) Heparin-induced thrombopenia. (springer.com)
  • 1995) Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. (springer.com)
  • Treatment of heparin-induced thrombocytopenia involves discontinuing heparin and starting a non-heparin anticoagulant. (medscape.com)
  • These patients most likely have an acute infection, heparin-induced thrombocytopenia, liver disease, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome, disseminated intravascular coagulation, or a hematologic disorder. (aafp.org)
  • A test for heparin-induced thrombocytopenia (HIT) antibody, also called heparin-PF4 antibody, is performed to detect antibodies that develop in some people who have been treated with heparin. (labtestsonline.org)
  • It is used to help establish a diagnosis of immune-mediated heparin-induced thrombocytopenia (HIT type II) in someone who has a low platelet count ( thrombocytopenia ) and excessive clotting ( thrombosis ). (labtestsonline.org)
  • Therefore, this test is most useful in those with a moderate to high likelihood of having HIT II, based upon the timing of heparin use, significant thrombocytopenia, and thrombosis. (labtestsonline.org)
  • The presence of HIT antibodies in someone who has received heparin within the last 3 months and is experiencing significant thrombocytopenia within a day or two of re-starting heparin therapy may also indicate HIT II. (labtestsonline.org)
  • In addition to heparin, there are several other medications that can cause drug-induced thrombocytopenia and antiplatelet antibodies. (labtestsonline.org)
  • Heparin-induced thrombocytopenia type I (HIT type I) may be seen in people who are receiving heparin, but HIT I tends to be a more mild condition that is not associated with an immune reaction and is typically of no clinical significance. (labtestsonline.org)
  • Thrombocytopenia may be associated with a variety of conditions, with associated risks that may range from life-threatening bleeding or thrombosis (eg, in heparin-induced thrombocytopenia [HIT]) to no risk at all. (uptodate.com)
  • Heparin-induced thrombocytopenia ( HIT ) is the development of thrombocytopenia (a low platelet count), due to the administration of various forms of heparin , an anticoagulant . (wikipedia.org)
  • When thrombosis is identified the condition is called heparin-induced thrombocytopenia and thrombosis ( HITT ). (wikipedia.org)
  • [1] [7] HIT antibodies have been found in individuals with thrombocytopenia and thrombosis who had no prior exposure to heparin, but the majority are found in people who are receiving heparin. (wikipedia.org)
  • Formation of PF4-heparin antibodies is common in people receiving heparin, but only a proportion of these develop thrombocytopenia or thrombosis. (wikipedia.org)
  • This condition is called heparin-induced thrombocytopenia (HIT). (nih.gov)
  • The report provides the segmentation of the disease epidemiology for 7MM by Prevalent Cases of Thrombotic Thrombocytopenic Purpura (TTP), Prevalent Cases of Immune Thrombocytopenia (ITP), Prevalent Cases of Thrombocytopenia in Chronic Liver Disease, Incident Cases of Chemotherapy-induced Thrombocytopenia, Number of Cases of Heparin-induced Thrombocytopenia, and Total Cases of Thrombocytopenia. (reportlinker.com)
  • Heparin-induced thrombocytopenia is unlikely because the heparin was discontinued 4 days before onset of thrombocytopenia and the negative heparin-dependent platelet antibody. (ahajournals.org)
  • Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. (ahajournals.org)
  • Heparin, a blood thinner, is the most common cause of drug-induced immune thrombocytopenia. (floridahealthfinder.gov)
  • Here we discuss the clinical and laboratory evaluation of drug-induced thrombocytopenia based on the description of two patients, one with ceftriaxone-induced thrombocytopenia and the other with heparin-induced thrombocytopenia. (ntvg.nl)
  • Heparin-induced thrombocytopenia (HIT) arises due to an immune-mediated destruction of platelets that may occur with the blood thinner heparin and its related drugs. (emedicinehealth.com)
  • Heparin-induced thrombocytopenia (HIT) is a complication of heparin therapy. (aruplab.com)
  • Heparin-induced Thrombocytopenia and the Serotonin Release Assay. (aruplab.com)
  • Induced thrombocytopenia heparin and IIb / IIIa glycoproteins (abciximab, tirofiban, epifibatide). (clinicaltrials.gov)
  • Summary Heparin-induced thrombocytopenia (HIT), typically occurring in the second week of he-parin therapy, is an antibody-mediated ad-verse drug reaction associated with increased thrombotic risk. (psu.edu)
  • A diagnostic test for heparin-induced thrombocytopenia . (psu.edu)
  • Heparin-induced thrombocytopenia can be a serious and difficult-to-diagnose complication of heparin therapy. (psu.edu)
  • American Society of Hematology 2019 guidelines for immune thrombocytopenia. (nih.gov)
  • Laboratory findings of patient with severe fever with healthy and without symptoms during the monitoring thrombocytopenia syndrome virus infection, Taiwan, 2019. (cdc.gov)
  • Patients with isolated thrombocytopenia commonly have drug-induced thrombocytopenia, immune thrombocytopenic purpura, pseudothrombocytopenia, or if pregnant, gestational thrombocytopenia. (aafp.org)
  • Gestational thrombocytopenia is common and does not pose a risk to the fetus or mother. (aafp.org)
  • What Is Gestational Thrombocytopenia? (wisegeek.com)
  • Gestational thrombocytopenia is a low platelet count in pregnancy that is usually benign. (wisegeek.com)
  • Typically, women with gestational thrombocytopenia can deliver vaginally and shouldn't experience additional risks in pregnancy because of their platelet counts, although other medical conditions could create complications. (wisegeek.com)
  • Patients with gestational thrombocytopenia are asymptomatic and don't have a history of bleeding during the pregnancy, indicating that the reduced number of platelets is not causing any problems. (wisegeek.com)
  • If a patient meets all these criteria, she likely has gestational thrombocytopenia rather than a more serious platelet-related condition. (wisegeek.com)
  • Patients with cases of gestational thrombocytopenia can be monitored to see if they develop symptoms or their platelets keep dropping, both indicators that something more serious is going on and intervention may be necessary. (wisegeek.com)
  • Although women with normal pregnancy experience a low platelet count, women experiencing a continuous drop in platelet will be diagnosed with thrombocytopenia and women with levels greater than 70,000 / μL will be diagnosed with gestational thrombocytopenia. (wikipedia.org)
  • approximately 70-80% have gestational thrombocytopenia Gestational Thrombocytopenia is a disorder similar to immune thrombocytopenia (ITP) and is difficult to differentiate between the two disorders. (wikipedia.org)
  • Gestational thrombocytopenia will become evident during the mid-second trimester through the third trimester of pregnancy and it is diagnosed based on exclusion. (wikipedia.org)
  • For example, women with a history of immune thrombocytopenia or thrombocytopenia, prior to pregnancy, will not be diagnosed with gestational thrombocytopenia. (wikipedia.org)
  • The reason is because low platelet counts maybe due to gestational thrombocytopenia or immune thrombocytopenia. (wikipedia.org)
  • If there is an improvement in the platelet levels, the patient will be diagnosed with immune thrombocytopenia, and if not the patient will be diagnosed with severe gestational thrombocytopenia In order for the physician to determine the underlying cause of the gestational thrombocytopenia, the following tests are conducted - During routine prenatal checkups, the physician will conduct a complete blood count test to determine the components of blood. (wikipedia.org)
  • Tarantino MD. Treatment options for chronic immune (idiopathic) thrombocytopenia purpura in children. (medscape.com)
  • As if he is referring to 287.31 Ideopathic Thrombo-coytopenia Purpura ITP, or 287.5 Thrombocytopenia unspecified. (aapc.com)
  • Symptoms of thrombocytopenia often include nosebleeds, bleeding in the mouth, easy or excessive bruising, prolonged bleeding from cuts, blood in stools, blood in urine, blood in vomit, purpura (purplish discolorations in the skin produced by small bleeding vessels near the surface of the skin), unusually heavy menstrual flows, profuse bleeding during surgery and superficial bleeding into the skin (that looks like a rash). (wellness.com)
  • In more serious cases of thrombocytopenia, the spots are larger and more widespread (purpura). (uwhealth.org)
  • 2. Idiopathic thrombocytopenia purpura. (medindia.net)
  • 4. Thrombotic thrombocytopenia purpura. (medindia.net)
  • Immune thrombocytopenia (ITP), sometimes called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when your child's body attacks its own platelets and destroys them too quickly. (childrenshospital.org)
  • Immune thrombocytopenia - or immune thrombocytopenic purpura (ITP) - happens when the immune system , which fights germs and infections, attacks the body's platelets. (akronchildrens.org)
  • Drug-induced thrombocytopenia can present with asymptomatic thrombocytopenia, hemolytic-uremic syndrome (HUS), or thrombotic thrombocytopenia purpura (TTP) in extreme cases [ 2 ]. (hindawi.com)
  • Signs of thrombocytopenia can include small pinpoint hemorrhages (petechiae) or bruises known as purpura. (emedicinehealth.com)
  • Immune Thrombocytopenia (ITP) in the past has been called Idiopathic Thrombocytopenia Purpura and Immune Thrombocytopenic Purpura. (oncologynurseadvisor.com)
  • Guidance document on how to deal with a patient presenting to ED or acute medicine with COVID-19 vaccine-induced thrombosis and thrombocytopenia (VITT). (medworm.com)
  • The condition of concern is Covid-19 Vaccine induced Thrombosis and Thrombocytopenia (VITT). (medworm.com)
  • TUESDAY, April 13, 2021 -- While rare, thrombosis and thrombocytopenia can occur after the ChAdOx1 nCoV-19 adenoviral vector vaccine against COVID-19 (AstraZeneca), according to two reports published online April 9 in the New England Journal of. (medworm.com)
  • The majority of people who produce HIT antibodies will not develop HIT II (i.e., have significant thrombocytopenia and thrombosis ). (labtestsonline.org)
  • The clinician is faced with distinguishing among many possible causes of thrombocytopenia and determining the risks of bleeding, thrombosis, and other potential complications. (uptodate.com)
  • Thrombocytopenia can be caused by either too little production of platelets in the bone marrow or by excessive destruction of circulating platelets. (netdoctor.co.uk)
  • a primary form of thrombocytopenia, in contrast to secondary forms that are associated with metastatic neoplasms, tuberculosis , and leukemia involving the bone marrow, or with direct suppression of bone marrow by the use of chemical agents, or with other conditions. (drugs.com)
  • Once thrombocytopenia has been diagnosed, a bone marrow biopsy can be performed to determine whether the bone marrow is producing a sufficient number of platelets. (wellness.com)
  • If a medicine prevents your bone marrow from making enough platelets, the condition is called drug-induced nonimmune thrombocytopenia. (floridahealthfinder.gov)
  • CAMT is caused by the congenital loss of thrombopoietin receptor-mediated intracellular signaling, resulting in a state of severe thrombocytopenia from birth and leading in the infant period to bone marrow failure and gradual depletion first of red blood cells and then of white blood cells. (medindia.net)
  • Viral infections may cause thrombocytopenia due to their effect on bone marrow, leading to decreased production of platelets. (emedicinehealth.com)
  • Many chemotherapeutic drugs commonly cause bone marrow toxicity and thrombocytopenia. (emedicinehealth.com)
  • citation needed] In severe thrombocytopenia, a bone marrow study can determine the number, size, and maturity of the megakaryocytes. (wikipedia.org)
  • The two main causes of thrombocytopenia are a decrease in the production of platelets in the bone marrow and an increase in the destruction of the platelets. (wikipedia.org)
  • People with immune thrombocytopenia produce antibodies that attack normal platelets. (medlineplus.gov)
  • Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines. (springer.com)
  • If a medicine causes your body to produce antibodies, which seek and destroy your platelets, the condition is called drug-induced immune thrombocytopenia. (floridahealthfinder.gov)
  • The most common reason for thrombocytopenia is when a mother's immune system makes antibodies against the baby's platelets. (rochester.edu)
  • Thrombocytopenia may be caused by antibodies attacking the baby's platelets. (rochester.edu)
  • The Immunology Laboratory of the University Hospital of Saint-Etienne has developed a biological test of thrombocytopenia induction in the presence of the drug and the patient's serum that is to say its antibodies and complement fractions with cytometry reading flow. (clinicaltrials.gov)
  • X-linked thrombocytopenia, also referred to as XLT or thrombocytopenia 1, is an inherited clotting disorder that primarily affects males. (wikipedia.org)
  • This form of thrombocytopenia is inherited on X chromosome, thus individuals with this disorder are typically males. (wikipedia.org)
  • Treatment for individuals with X-linked thrombocytopenia is typically focused on managing symptoms of the disorder. (wikipedia.org)
  • Immune thrombocytopenia is a disorder characterized by a blood abnormality called thrombocytopenia, which is a shortage of blood cells called platelets that are needed for normal blood clotting. (medlineplus.gov)
  • such as a parent or sibling) with immune thrombocytopenia likely have an increased risk of developing the disorder themselves. (medlineplus.gov)
  • Thrombocytopenia is any disorder in which there is an abnormally low amount of platelets. (medlineplus.gov)
  • I saw the haematologist yesterday and was told that I have a blood disorder called familial thrombocytopaenia . (netdoctor.co.uk)
  • ANKRD26 -related thrombocytopenia is a nonsyndromic congenital thrombocytopenia disorder lacking pathognomonic features and thus requiring molecular confirmation of a heterozygous ANKRD26 pathogenic variant to establish a diagnosis. (nih.gov)
  • Patients who present with thrombocytopenia as part of a multisystem disorder usually are ill and require urgent evaluation and treatment. (aafp.org)
  • Immune thrombocytopenia is a bleeding disorder. (drugs.com)
  • Thrombocytopenia is a blood disorder that is caused by a low platelet count. (cookchildrens.org)
  • Immune thrombocytopenia (ITP) is a disorder that can lead to easy or excessive bruising and bleeding. (mayoclinic.org)
  • Another common type of bleeding disorder is called thrombocytopenia. (mskcc.org)
  • Thrombocytopenia is a disorder in which there are too few platelets and the blood does not clot properly. (uwhealth.org)
  • Thrombocytopenia-absent radius (TAR) syndrome is a rare disorder that is present at birth (congenital). (rarediseases.org)
  • Thrombocytopenia with Absent Radii (TAR), is a rare, inherited disorder of the blood and skeletal system. (medindia.net)
  • Thrombocytopenia is a disorder in which there are not enough platelets. (blausen.com)
  • Chemotherapy-induced thrombocytopenia is a disorder that develops as an adverse effect of chemotherapy. (blausen.com)
  • The typical patient with ITP presents with either asymptomatic thrombocytopenia or with a bleeding disorder. (oncologynurseadvisor.com)
  • DURHAM, N.C. , March 15, 2021 /PRNewswire/ -- Sobi ™, a North American affiliate of the international biopharmaceutical company Swedish Orphan Biovitrum AB (publ) (Sobi®), dedicated to rare diseases, in partnership with the Platelet Disorder Support Association ( www.pdsa.org PDSA), a leading immune thrombocytopenia (ITP) advocacy organization in North America , today announced the launch of florio®ITP, an app for patients living with ITP. (prnewswire.com)
  • The Platelet Disorder Support Association (PDSA) is dedicated to enhancing the lives of people with immune thrombocytopenia (ITP) and other platelet disorders through education, advocacy, research and support. (prnewswire.com)
  • Reduced megakaryocyte (MK) apoptosis and insufficient platelet production play important roles in the pathogenesis of immune thrombocytopenia (ITP). (nih.gov)
  • Severe fever with thrombocytopenia syndrome virus (SFTSV) is a tickborne virus (genus Phlebovirus, family Phenuiviridae) that can cause a mild to severe febrile illness similar to hemorrhagic fever (1). (thefreedictionary.com)
  • During pregnancy, preeclampsia and the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome are associated with thrombocytopenia. (aafp.org)
  • Patients older than 60 years with thrombocytopenia should be evaluated for myelodysplastic syndrome or lymphoproliferative disorders. (aafp.org)
  • Severe fever with thrombocytopenia syndrome virus (SFTSV) is a globe-shaped virus covered by a dense icosahedral array of glycoproteins Gn/Gc that mediate the attachment of the virus to host cells and the fusion of viral and cellular membranes. (springer.com)
  • Immune thrombocytopenia (ITP) is a syndrome in which platelets become coated with autoantibodies to platelet membrane antigens, resulting in splenic sequestration and phagocytosis by mononuclear macrophages. (medscape.com)
  • In addition, human-to-human transmis- with thrombocytopenia syndrome (SFTS) in Japan dur- ing 2013-2017. (cdc.gov)
  • Severe Fever with Thrombocytopenia Syndrome, Japan parameters were associated with a fatal outcome of during October 2014-October 2017. (cdc.gov)
  • The normal maturation of megakaryocytes into platelets does not occur in individuals with TAR syndrome, causing the low levels of platelets, which may be referred to as (hypomegakaryocytic thrombocytopenia). (rarediseases.org)
  • Severe fever with thrombocytopenia syndrome severe disease and death ( 5 ). (cdc.gov)
  • Severe fever with thrombocytopenia syndrome (SFTS) is an emerging hemorrhagic fever caused by a tick-borne banyangvirus and is associated with high fatality. (jci.org)
  • Severe fever with thrombocytopenia syndrome phlebovirus (SFTSV), listed in the most dangerous pathogens by the World Health Organization, has 12-30% fatality rates with a characteristic thrombocytopenia syndrome. (nature.com)
  • Thrombocytopenia in pregnancy with different diagnoses: Differential clinical features, treatments, and outcomes. (medscape.com)
  • Balduini CL, Melazzini F, Pecci A. Inherited thrombocytopenias-recent advances in clinical and molecular aspects. (medscape.com)
  • Here we discuss our approach to the adult patient with unexpected thrombocytopenia, divided according to clinical presentation (eg, asymptomatic, associated with another condition, acutely ill hospitalized patient). (uptodate.com)
  • Because the hematology and oncology team at Cook Children's has extensive experience in the causes, diagnosis and treatment of thrombocytopenia, you can trust that your child will have access to the latest advancements in medical treatment including research and clinical trials . (cookchildrens.org)
  • Immune thrombocytopenia (ITP) in adults: Clinical manifestations and diagnosis. (mayoclinic.org)
  • The majority of patients with thrombocytopenia in pregnancy will have incidental thrombocytopenia of pregnancy which is of no clinical significance. (mendeley.com)
  • Whereas young adult ferrets (≤2 years of age) did not show any clinical symptoms and mortality, SFTSV-infected aged ferrets (≥4 years of age) demonstrated severe thrombocytopenia, reduced white blood cell counts and high fever with 93% mortality rate. (nature.com)
  • As per the analysis, the total number of cases of Thrombocytopenia in the 7MM was 1,653,934 in 2020. (reportlinker.com)
  • These cases of Thrombocytopenia in the 7MM are expected to increase throughout the study period i.e. 2018-2030, with CAGR of 0.66% for the study period 2018-2030. (reportlinker.com)
  • Most cases of thrombocytopenia are not serious enough to need treatment. (rochester.edu)
  • Aside from observing the symptoms characteristic of X-linked thrombocytopenia in infancy (easy bruising, mild anemia, mucosal bleeding), molecular genetic testing would be done to confirm the diagnosis. (wikipedia.org)
  • ANKRD26 -related thrombocytopenia is characterized by lifelong mild-to-moderate thrombocytopenia with a normal platelet size and no syndromic associations. (nih.gov)
  • Patients with mild thrombocytopenia (i.e., platelet counts of 100 to 150 × 10 3 per μL [100 to 150 × 10 9 per L]) who are asymptomatic should have a platelet count repeated in two to four weeks. (aafp.org)
  • Pregnancy may also cause mild thrombocytopenia. (wellness.com)
  • Symptoms of thrombocytopenia can range from mild to severe. (wellness.com)
  • Mild thrombocytopenia often causes no signs or symptoms. (wellness.com)
  • Petechiae over the ankles in ambulatory patients or on the back in bedridden ones suggest mild thrombocytopenia and a relatively low risk for a serious bleeding complication. (medscape.com)
  • About 5 percent of pregnant women develop mild thrombocytopenia when they're close to delivery. (nih.gov)
  • In addition, in rhesus macaques, SFTSV does not cause severe symptoms or death but causes fever, thrombocytopenia and leukocytopenia, suggesting that rhesus monkey infection resembles only a mild form of SFTSV infection in humans 20 . (nature.com)
  • Thrombocytopenia is a condition characterised by low levels of platelets, so the patients' bodies cannot form clots and their symptoms include uncontrollable bleeding that can lead to hematomas and haemorrhages. (eurekalert.org)
  • Thrombocytopenia is a condition characterized by abnormally low levels of platelets, also known as thrombocytes, in the blood. (wikipedia.org)
  • Studies have indicated that various haematological abnormalities like anaemia, thrombocytopenia , atypical lymphocytosis, rarely disseminated intravascular coagulation (DIC) are associated with malaria. (thefreedictionary.com)
  • The aetiology is often not recognised or is ascribed to other complications such as disseminated intravascular coagulation (DIC) or immune thrombocytopenia (ITP). (ntvg.nl)
  • Immune thrombocytopenia may also be called idiopathic thrombocytopenia or ITP. (drugs.com)
  • Idiopathic thrombocytopenia and neutropenia in childhood. (biomedsearch.com)
  • ANKRD26 -related thrombocytopenia is inherited in an autosomal dominant manner. (nih.gov)
  • The thrombocytopenia found in these patients, caused by the mutation on MASTL is known as autosomal dominant thrombocytopenia or thrombocytopenia-2. (eurekalert.org)
  • However, immune thrombocytopenia can be a feature of other immune disorders, such as common variable immune deficiency , which occurs when the immune system has a decreased ability to protect the body against foreign invaders, or other autoimmune disorders such as systemic lupus erythematosus . (medlineplus.gov)
  • Thrombocytopenia occurs in people without cancer as well. (mskcc.org)
  • 1 The thrombocytopenia so caused usually occurs within 24 hours of infusion, and it underscores the importance of the close monitoring of platelet count after infusion. (ahajournals.org)
  • Drug-induced thrombocytopenia occurs when certain medicines destroy platelets or interfere with the body's ability to make enough of them. (floridahealthfinder.gov)
  • Thrombocytopenia occurs because there is decreased production or increased destruction of platelets. (emedicinehealth.com)
  • The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. (medscape.com)
  • Once the hematology and oncology team has diagnosed the cause and type of your child's thrombocytopenia, your pediatric specialist will provide a plan of care and treatment. (cookchildrens.org)
  • https://www.merckmanuals.com/professional/hematology-and-oncology/thrombocytopenia-and-platelet-dysfunction/immune-thrombocytopenia-itp?query=immune%20thrombocytopenia. (mayoclinic.org)
  • City of Hope is committed to advancing the medical community's understanding of myelofibrosis and thrombocytopenia through research studies," said David S. Snyder , M.D., associate chair of the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope. (cityofhope.org)
  • Rajan et al, 2001, Treatment of Hepatitis C related thrombocytopenia with interferon alpha, Amer Jour of Hematology, 68: 202-209. (freepatentsonline.com)
  • Thrombocytopenia can happen with any drug, but you should also have a complete hematology work up done if the platelets don't rebound within a few months. (doctorslounge.com)
  • Myelofibrosis patients often suffer from severely low blood platelets, or thrombocytopenia. (cityofhope.org)
  • 2. The method of claim 1, wherein the thrombocytopenia is due to a reduction of blood platelets in the patient receiving the interferon-alpha intravenously. (freepatentsonline.com)
  • Thrombocytopenia also develops in 5% of normal pregnant women, in patients receiving excessive blood transfusions, and in enlarged spleens containing nearly 90% of blood platelets. (medindia.net)
  • Immune-mediated thrombocytopenia (IMT) is a condition in which the body's immune system attacks and destroys blood platelets. (vetstreet.com)
  • Many conditions and diseases other than HIT can cause thrombocytopenia by affecting platelet production or increasing platelet loss (destruction). (labtestsonline.org)
  • Drug-induced immune thrombocytopenia is attributed to decreased platelet production secondary to myelosuppression or accelerated platelet destruction secondary to an immune response [ 1 ]. (hindawi.com)
  • This information may identify ineffective platelet production as the cause of thrombocytopenia and rule out a malignant disease process at the same time. (wikipedia.org)
  • CASE REPORT: We report a case of severe thrombocytopenia related to trastuzumab administration. (biomedsearch.com)
  • We present a rare case of severe thrombocytopenia associated with administration of azithromycin. (hindawi.com)
  • What are the signs and symptoms of immune thrombocytopenia? (drugs.com)
  • People with immune thrombocytopenia can have significant bleeding episodes, such as nose bleeds (epistaxis) or bleeding in the moist lining (mucosae) of the mouth. (medlineplus.gov)
  • In some people with immune thrombocytopenia, the abnormal immune reactions may coincide with an infection by certain viruses or bacteria. (medlineplus.gov)
  • Genetic variations (polymorphisms) in a few genes have been found in some people with immune thrombocytopenia and may increase the risk of abnormal immune reactions. (medlineplus.gov)
  • Sometimes no treatment is needed and the thrombocytopenia clears up on its own. (kidshealth.org)
  • Treatment usually addresses the condition causing the thrombocytopenia. (healthline.com)
  • Alliance News) - Hutchison China Meditech Ltd on Friday said it has begun a phase 1 study of HMPL-523 as a treatment for immune thrombocytopenia in China, dosing the first patient on Monday last week. (thefreedictionary.com)
  • Dova's proprietary pipeline includes one commercial product, DOPTELET, for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure and the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. (thefreedictionary.com)
  • This collaboration is an important milestone for patients in China living with chronic liver disease, bringing a well-tolerated and effective treatment option for severe thrombocytopenia that facilitates the management of invasive procedures one step closer to these patients. (thefreedictionary.com)
  • Consultation with a hematologist should be considered if patients require hospitalization, if there is evidence of systemic disease, or if thrombocytopenia worsens despite initial treatment. (aafp.org)
  • Sanofi's rilzabrutinib was granted fast track designation by the FDA as a treatment for immune thrombocytopenia based on positive results from a Phase I/II trial. (smartbrief.com)
  • Severe thrombocytopenia confers a greater risk of bleeding and implies a greater likelihood for needing treatment, but the correlation between the platelet count and the risk of bleeding varies according to the underlying condition and may be unpredictable. (uptodate.com)
  • Immune thrombocytopenia (ITP) in adults: Initial treatment and prognosis. (mayoclinic.org)
  • Chronological correlation of platelet levels and hemodialysis sessions demonstrated a consistent decrease in platelet levels following each hemodialysis treatment (Figure 1 ) at which point it was suspected that thrombocytopenia was likely dialysis induced. (hindawi.com)
  • Treatment for thrombocytopenia depends on the underlying cause of the low platelet count. (petplace.com)
  • Among the reported cases of trastuzumab-induced severe thrombocytopenia, this patient is the only one who did not interrupt trastuzumab treatment. (biomedsearch.com)
  • Normalisation of thrombocytopenia was only achieved after initiation of anti-tuberculosis treatment following failure of thrombocyte substitution and immune-modulatory treatment. (ingentaconnect.com)
  • Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. (bmj.com)
  • A woman developed thrombocytopenia, first noticed as a reduction in the platelet count to a low-normal value, 17 days after treatment with carvedilol was begun. (ebscohost.com)
  • This study demonstrates the high prevalence of thrombocytopenia among Romanian patients with HCV infection and due to the size of the study we can estimate also its prevalence during antiviral treatment which still influences the therapy decisions and the rate of sustained virologic response," the researchers wrote. (healio.com)
  • Treatment usually depends on the cause of the thrombocytopenia. (rochester.edu)
  • We report on a 70-year-old man with fever, leukopenia, tion, he received treatment with intravenous immu- thrombocytopenia, vomiting, malaise, dyspnea, and con- noglobulin for 5 days. (cdc.gov)
  • This study will test the safety and efficacy of this investigational drug in the prevention of thrombocytopenia in patients with solid tumors, lymphomas or multiple myeloma who are receiving myelosuppressive treatment regimens requiring platelet transfusion support. (pfizer.com)
  • Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Patients Receiving Myelosuppressive Treatment Regimens Requiring Platelet Transfusion Support. (pfizer.com)
  • Treatment of thrombocytopenia, when necessary, consists of platelet transfusions. (emedicinehealth.com)
  • One common definition of thrombocytopenia requiring emergency treatment is a platelet count below 50,000 per microliter. (wikipedia.org)
  • Diagnosis and treatment of serious thrombocytopenia is usually directed by a hematologist. (wikipedia.org)
  • In such cases, a treatment of immune thrombocytopenia therapy (corticosteroids, or intravenous immunoglobulin) will be instructed. (wikipedia.org)
  • Thrombocytopenia in neonates and children, and thrombocytopenia during pregnancy are discussed separately. (uptodate.com)
  • See 'Causes of neonatal thrombocytopenia' and 'Causes of thrombocytopenia in children' and 'Thrombocytopenia in pregnancy' . (uptodate.com)
  • Thrombocytopenia in pregnancy: di. (mendeley.com)
  • Maternal thrombocytopenia is a common finding during pregnancy. (mendeley.com)
  • It is the leading cause of thrombocytopenia in pregnancy and is not at all uncommon, although a patient's obstetrician may request some additional testing to confirm the diagnosis and rule out other possible causes of a low platelet count . (wisegeek.com)
  • Patients with stable thrombocytopenia (platelet counts greater than 50 × 10 3 per μL) generally do not require activity restrictions and are able to tolerate most invasive procedures. (aafp.org)
  • In some cases, this causes platelet counts to dip below the diagnostic threshold for thrombocytopenia. (wisegeek.com)
  • The severely low platelet counts, known as thrombocytopenia, that are one of the hallmark symptoms of the disease can lead to chronic fatigue and weakness that not only damage quality of life but, ultimately, shorten life span. (cityofhope.org)
  • City of Hope is now testing a new drug, pacritinib , that could help boost those platelet counts in myelofibrosis patients with thrombocytopenia . (cityofhope.org)
  • Drug-induced thrombocytopenia can result in severe, progressive reductions in platelet counts with resultant sequelae of bleeding [ 1 - 3 ]. (hindawi.com)
  • Drug-induced thrombocytopenia results in severely decreased platelet counts, often less than 20,000/ μ L [ 3 ]. (hindawi.com)
  • Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. (pfizer.com)
  • In severe thrombocytopenia (platelet counts of less than 10,000 to 20,000), excess bleeding can occur if the person is cut or injured. (emedicinehealth.com)
  • 1 , 10 , 12 In the case reported here, olanzapine would not have been discontinued if an early distinction between pseudothrombocytopenia and drug-induced immune thrombocytopenia had been made. (slideshare.net)
  • Individuals who have an enlarged spleen are at risk for developing thrombocytopenia. (wellness.com)
  • PORTLAND, Oregon-A phase III study presented at the ASH meeting shows that oprel-vekin (rhIL-11, Neumega) effectively prevents severe chemotherapy-induced thrombocytopenia. (cancernetwork.com)
  • Fortunately, chemotherapy-induced thrombocytopenia can be managed with platelet transfusions, additional medications, such as blood cell growth factors, or with blood stem cell transplants. (blausen.com)
  • Tavalisse (fostamatinib) was granted approval by the Food and Drug Administration (FDA) for patients with chronic immune thrombocytopenia (ITP) after they had an insufficiencent response to another therapy. (curetoday.com)
  • When the condition is due to the targeted destruction of platelets by the body's own immune cells, it is known as primary immune thrombocytopenia. (medlineplus.gov)
  • How is immune thrombocytopenia diagnosed? (drugs.com)
  • Most cases of childhood immune thrombocytopenia happen in kids 1-7 years old. (akronchildrens.org)
  • What is congenital amegakaryocytic thrombocytopenia (CAMT)? (childrensmn.org)
  • What are the symptoms of congenital amegakaryocytic thrombocytopenia (CAMT)? (childrensmn.org)
  • Symptoms for congenital amegakaryocytic thrombocytopenia include bruising and bleeding, which can be life threatening. (childrensmn.org)
  • How is congenital amegakaryocytic thrombocytopenia (CAMT) diagnosed? (childrensmn.org)
  • How is congenital amegakaryocytic thrombocytopenia (CAMT) treated? (childrensmn.org)
  • Researchers led by Shinji Hirata and Professor Koji Eto at CiRA reveal that they have managed to induce iPS cells generated from a patient with congenital amegakaryocytic thrombocytopenia (CAMT) to differentiate into blood cells in vitro which were then used to conduct a detailed study of the differences between these cells and cells from healthy subjects. (medindia.net)
  • Specific symptoms of thrombocytopenia include frequent nosebleeds or gastrointestinal bleeding, which can result in the vomiting of blood (hematemesis) or bloody stools. (rarediseases.org)
  • Some individuals with thrombocytopenia may experience external bleeding such as nosebleeds, or bleeding gums. (wikipedia.org)
  • One of the most common causes of low platelets is a condition called immune thrombocytopenia (ITP). (webmd.com)
  • In 2009, an emerging infectious disease that caused severe fever, thrombocytopenia and leukocytopenia with a high fatality rate was first reported in China 1 . (nature.com)
  • Diagnosis of thrombocytopenia can be made with a simple blood test called the complete blood count . (medindia.net)
  • The common occurrence of thrombocytopenia and its association with acute renal failure in patients with leptospirosis has not previously been reported. (ajtmh.org)

No images available that match "thrombocytopenia"